<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1307210863
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Turbo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SILDENAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oromucosal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Orodispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TURBO ODT contains the active substance sildenafil which belongs to a class of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It helps relax the blood vessels in the penis, allowing blood to flow to the penis when it is sexually stimulated. TURBO ODT will help you get an erection only if you are sexually stimulated.</p><p>&nbsp;</p><p>TURBO ODT is a treatment for adult men with erectile dysfunction, sometimes called impotence. This condition occurs when a man is unable to achieve or maintain an erection suitable for sexual intercourse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take TURBO</strong> <strong>ODT:</strong></p><p>-&nbsp; &nbsp; &nbsp; if you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take medicines called nitrates, as this combination can cause a dangerous lowering of blood pressure. Tell your doctor if you are taking any of these medicines which are often used to relieve attacks of angina pectoris (or &#39;chest pain&#39;). If you are unsure, please consult your doctor or pharmacist.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the medicines known as nitric oxide donors, such as amyl nitrite (&#39;poppers&#39;), as this combination can also cause a dangerous fall of blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as TURBO ODT have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe heart or liver problem.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recently had a stroke or a heart attack, or if you have low blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have certain rare inherited eye diseases (such as retinitis pigmentosa).</p><p>-&nbsp; &nbsp; &nbsp; If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy (NAION).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking TURBO ODT</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a deformity of your penis or Peyronie&rsquo;s Disease.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have problems with your heart. Your doctor should carefully check whether your heart can take the additional strain of having sex.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you currently have a stomach ulcer, or a bleeding problem (such as haemophilia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience sudden decrease or loss of vision, stop taking TURBO and contact your doctor immediately.</p><p>&nbsp;</p><p>You should not use TURBO ODT with any other oral or local treatments for erectile dysfunction.</p><p>&nbsp;</p><p>You should not use TURBO ODT with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors.</p><p>&nbsp;</p><p>You should not take TURBO ODT if you do not have erectile dysfunction.</p><p>&nbsp;</p><p>You should not take TURBO ODT if you are a woman.</p><p>&nbsp;</p><p><strong>Special considerations for patients with kidney or liver problems</strong></p><p>You should tell your doctor if you have kidney or liver problems. Your doctor may decide on a lower dose for you.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>TURBO ODT should not be given to individuals under the age of 18.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and TURBO</strong> <strong>ODT</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>TURBO ODT tablets may interfere with some medicines, especially those used to treat chest pain. In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken TURBO ODT and when you did. Do not take TURBO ODT with other medicines unless your doctor tells you that you can.</p><p>&nbsp;</p><p>You should not take TURBO ODT if you are taking medicines called nitrates, as the combination of these medicines may lead to a dangerous fall in your blood pressure. Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or &ldquo;chest pain&rdquo;).</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are already taking riociguat.</p><p>&nbsp;</p><p>You should not take TURBO if you are using any of the medicines known as nitric oxide donors such as amyl nitrite (&ldquo;poppers&rdquo;) as the combination may also lead to a dangerous fall in your blood pressure.</p><p>&nbsp;</p><p>If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25 mg) of Sildenafil.</p><p>&nbsp;</p><p>Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly. Certain patients have experienced these symptoms when taking TURBO ODT with alpha-blockers. This is most likely to happen within 4&nbsp;hours&nbsp;</p><p>after taking TURBO ODT. To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start TURBO. Your doctor may start you on a lower dose (25 mg tablets) of Sildenafil.</p><p>&nbsp;</p><p><strong>TURBO ODT with alcohol</strong></p><p>Drinking alcohol can temporarily impair your ability to get an erection. To get the maximum benefit from your medicine, you are advised not to drink excessive amounts of alcohol before taking TURBO ODT.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>TURBO ODT is not indicated for use by women.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>TURBO ODT can cause dizziness and can affect vision. You should be aware of how you react to TURBO ODT before you drive or use machinery.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>You should not take TURBO ODT more than once a day.</strong></p><p>&nbsp;</p><p>Do not take TURBO orodispersible tablets in combination with film-coated tablets containing sildenafil including TURBO film coated tablets.</p><p>&nbsp;</p><p>You should take TURBO ODT about one hour before you plan to have sex. The amount of time TURBO ODT takes to work varies from person to person, but it normally takes between half an hour and one hour.</p><p>&nbsp;</p><p>Place the orodispersible tablet in the mouth, on the tongue, where it will dissolve in seconds, then swallow with saliva or water.</p><p>&nbsp;</p><p>The orodispersible tablets should be taken on an empty stomach as you may find that it takes longer to start working if you take it with a heavy meal.</p><p>&nbsp;</p><p>If you require a second 50 mg orodispersible tablet to make a 100 mg dose, you should wait until the first one has completely disintegrated and you have swallowed it before taking the second orodispersible tablet.</p><p>&nbsp;</p><p>If you feel that the effect of TURBO is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>TURBO ODT will only help you to get an erection if you are sexually stimulated.</p><p>&nbsp;</p><p>If TURBO ODT does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor.</p><p>&nbsp;</p><p><strong>If you take more TURBO ODT than you should:</strong></p><p>You may experience an increase in side effects and their severity. Doses above 100 mg do not increase the efficacy.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>You should not take more tablets than your doctor tells you to.</strong></p><p>&nbsp;</p><p>Contact your doctor if you take more tablets than you should.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, TURBO orodispersible tablets can cause side effects although not everybody gets them. The side effects reported in association with the use of TURBO ODT are usually mild to moderate and of a short duration.</p><p>&nbsp;</p><p><strong>If you experience any of the following serious side effects stop taking TURBO ODT and seek medical help immediately:</strong></p><p><strong>&nbsp;</strong></p><ul><li>An allergic reaction - this occurs <strong>uncommonly </strong>(may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.</li><li>Chest pains (this occurs <strong>uncommonly</strong>)</li></ul><p>If this occurs during or after intercourse:</p><p>- Get in a semi-sitting position and try to relax.</p><p>- <strong>Do not use nitrates </strong>to treat your chest pain.</p><ul><li>Prolonged and sometimes painful erections - this occurs <strong>rarely </strong>(may affect up to 1 in 1,000 people).</li></ul><p>If you have an erection which lasts for more than 4 hours, you should contact a doctor</p><p>immediately.</p><ul><li>A sudden decrease or loss of vision - this occurs <strong>rarely</strong></li><li>Severe skin reactions - this occur <strong>rarely</strong>.</li></ul><p>Symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever.</p><ul><li>Seizures or fits - this occurs <strong>rarely</strong>.</li></ul><p>&nbsp;</p><p><strong>Other side effects:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people): headache.</p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 people): nausea, facial flushing, hot flush (symptoms include a sudden feeling of heat in your upper body), indigestion, colour tinge to vision, blurred vision, visual disturbance, stuffy nose and dizziness.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people): vomiting, skin rash, bloodshot eyes /red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, lacrimation , pounding heartbeat, rapid heartbeat, , high blood pressure, low blood pressure, muscle pain, drowsiness, decreased sensitivity to touch, dizziness, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), blood in the urine, pain in the arms or legs, nosebleed and feeling hot.</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decreased blood flow to parts of the brain, feeling of tightening of the throat, numb mouth, bleeding at the back of the eyes, double vision, reduced sharpness of vision, abnormal sensation in the eye, swelling of the eye or eyelid, small dots or particles in your field of vision , seeing halos around lights, dilation of the pupils, change in white color of the sclera (part of the eye), penile bleeding, blood in semen, dry nose, swelling of the lining of the nose, irritability and sudden decrease or loss of hearing.</p><p>&nbsp;</p><p>From post-marketing experience cases of unstable angina (a heart condition) and sudden death have been reported rarely. Of note, most, but not all, of the men who experienced these side effects had heart problems before taking this medicine. It is not possible to determine whether these events were directly related to TURBO ODT.</p><p>&nbsp;</p><p><strong>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of reach and sight of children.</p><p>- Store below 30&deg;C.</p><p>- Store in the original carton.</p><p>- Do not use TURBO ODT after the expiry date which is stated on the blister and on the carton. The expiry date refers to the last day of the month.</p><p>- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is sildenafil. Each orodispersible tablet contains sildenafil citrate ( Ph.Eur) equivalent sildenafil 50 mg .</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: Mannitol, Microcrystalline cellulose, Crospovidone, Croscarmellose sodium, Sucralose, Povidone K-30, Lemon Flavour, Peppermint flavour (C-7531), Peppermint flavour P96511-71, Magnesium stearate, Purified water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Orodispersible tablets.
White to off white coloured,diamond shaped tablets, debossed with “CT42” on one side and plain on the other side.

Pack size:  
Alu/Alu Blister pack 4’s count 
Available in 2 packs 4 tablets per box & 8 tablets per box.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O.Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>For any information about this medicinal product, please contact the local representative of marketing authorisation holder:</em></p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was revised in (10/2020)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي توربو أو دي تي على المادة الفعالة سيلدينافيل التي تنتمي إلى فئة من الأدوية تسمى مثبطات فوسفودايستريس 5 (PDE5).</p><p dir="RTL">وهو يعمل عن طريق المساعدة على استرخاء الأوعية الدموية في العضو الذكري، مما يسمح بتدفق الدم الى العضو الذكري عند التهيج جنسيا. وهذا الدواء يساعدك فقط للحصول على الانتصاب إذا كنت تحفزت جنسيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توربو أو دي تي هو علاج للرجال البالغين الذين يعانون من ضعف الانتصاب ، ويسمى أحيانًا بالعجز الجنسي. تحدث هذه الحالة عندما يكون الرجل غير قادر على تحقيق الانتصاب المناسب للجماع أو الحفاظ عليه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول توربو</strong> <strong>أو دي تي</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من السيلدينافيل أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية تسمى النترات فان الجمع بينها قد يسبب انخفاضا قد يكون خطراً في ضغط الدم. أخبر طبيبك إذا كنت تتناول أي من هذه الأدوية التي غالبا ما تعطى لتخفيف الذبحة الصدرية (أو &quot;ألم الصدر&quot;). إذا كنت غير متأكد، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تستخدم أي من الأدوية المعروفة باسم مانحة أكسيد النيتريك مثل نتريت الأميل (&quot;بوبرس&quot;) فإن الجمع بينها قد يؤدي أيضا إلى انخفاض قد يكون خطراً في ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ريوسيجوات. يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي المزمن بسبب الانصمام الخثاري (أي ارتفاع ضغط الدم في الرئتين نتيجة تجلط الدم). ثبت أن مثبطات PDE5 ، مثل توربو أو دي تي تزيد من التأثيرات الخافضة للضغط لهذا الدواء. إذا كنت تتناول ريوسيجوات أو لم تكن متأكدًا أخبر طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة خطيرة في القلب أو الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت مؤخرًا بسكتة دماغية أو نوبة قلبية ، أو إذا كان لديك ضغط دم منخفض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك بعض أمراض العيون الوراثية النادرة (مثل التهاب الشبكية الصباغي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من فقدان البصر بسبب الاعتلال العصبي البصري الأمامي الدماغي اللاشرياني (NAION).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول توربو أو دي تي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فقر الدم المنجلي (خلل في خلايا الدم الحمراء) ، اللوكيميا (سرطان خلايا الدم) ، المايلوما المتعددة (سرطان نخاع العظام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تشوه في القضيب أو مرض بايرونيس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في قلبك. يجب على طبيبك في هذه الحالة التحقق بعناية ما إذا قلبك يمكن أن يتحمل عبئا إضافيا في ممارسة الجنس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني حاليًا من قرحة في المعدة أو مشكلة نزيف (مثل الهيموفيليا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض أو فقدان مفاجئ في الرؤية ، توقف عن تناول توربو أو دي تي واتصل بطبيبك على الفور.</p><p dir="RTL">يجب عدم استخدام هذا الدواء مع أي علاج عن طريق الفم أو الأدوية الموضعية الأخرى لعلاج عدم القدرة على الانتصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم استخدام توربو مع علاجات ارتفاع ضغط الدم الشرياني الرئوي (PAH) التي تحتوي على السيلدينافيل أو أي مثبطات PDE5 أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تتناول توربو إذا لم يكن لديك ضعف في الانتصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجب أن تتناولي توربو إذا كنتِ امرأة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات خاصة لمرضى الكلى أو الكبد</strong></p><p dir="RTL">يجب أن تخبر طبيبك إذا كنت تعاني من مشاكل في الكلى أو الكبد. قد يقرر طبيبك جرعة أقل لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي إعطاء توربو للأفراد الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتوربو</strong> <strong>أو دي تي</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">قد تتداخل أقراص توربو أو دي تي مع بعض الأدوية ، خاصة تلك المستخدمة لعلاج آلام الصدر. في حالة حدوث حالة طبية طارئة ، يجب أن تخبر طبيبك أو الصيدلي أو الممرضة أنك قد تناولت توربو ومتى قمت بذلك. لا تتناول توربو أو دي تي مع أدوية أخرى ما لم يخبرك طبيبك أنه يمكنك ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تتناول توربو أو دي تي إذا كنت تتناول أدوية تسمى النترات ، لأن الجمع بين هذه الأدوية قد يؤدي إلى انخفاض خطير في ضغط الدم لديك. أخبر طبيبك أو الصيدلي أو الممرضة دائمًا إذا كنت تتناول أيًا من هذه الأدوية التي غالبًا ما تستخدم للتخفيف من الذبحة الصدرية (أو &quot;ألم الصدر&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول ريوسيجوات بالفعل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تتناول توربو أو دي تي إذا كنت تستخدم أيًا من الأدوية المعروفة باسم مانح أكسيد النيتريك مثل أميل نيتريت (&quot;بوبرس&quot;) لأن الجمع بينهما قد يؤدي أيضًا إلى انخفاض خطير في ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول الأدوية المعروفة باسم مثبطات الأنزيم البروتيني، مثل التي تعالج فيروس نقص المناعة البشرية، فإن طبيبك قد يبدأ لك على أقل جرعة (25 ملجم) من السيلدينافيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض المرضى الذين يتناولون علاج مثبطات ألفا التي تعالج ارتفاع ضغط الدم أو تضخم البروستاتا قد تواجه دوخة أو دوار خفيف، والتي قد تكون ناجمة عن انخفاض ضغط الدم عند الجلوس أو الوقوف بسرعة. قد يتعرض بعض المرضى لهذه الأعراض عند تناول هذا الدواء مع مثبطات ألفا. هذا هو الأرجح أن يحدث في غضون 4 ساعات بعد تناول هذا الدواء. للحد من احتمال أن تحدث هذه الأعراض، يجب أن تتناول الجرعة اليومية المعتادة الخاصة بك من مثبطات ألفا قبل البدء في تناول توربو. طبيبك قد يبدأ بوصف جرعة منخفضة (25 ملجم) من السيلدينافيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توربو مع الكحول</strong></p><p dir="RTL">يمكن لشرب الكحول أن يضعف مؤقتًا من قدرتك على الانتصاب. للحصول على أقصى فائدة من دوائك ، يُنصح بعدم شرب كميات كبيرة من الكحول قبل تناول توربو أو دي تي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">لا داعي لاستعمال توربو أو دي تي من قبل النساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة و استخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب توربو أو دي تي الدوخة ويمكن أن يؤثر على الرؤية. يجب أن تكون على دراية بكيفية تأثير توربو أو دي تي عليك قبل القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. يجب عليك مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يجب ألا تتناول</strong><strong> </strong><strong>توربو</strong> <strong>أو دي تي</strong><strong> </strong><strong>أكثر من مرة في اليوم</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول أقراص توربو أو دي تي سريعة الذوبان في الفم مع أقراص أخرى مغلفة تحتوي على السيلدينافيل بما في ذلك أقراص توربو المغلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتناول توربو أو دي تي حوالي ساعة واحدة قبل أن تخطط لممارسة الجنس. يختلف مقدار الوقت الذي يستغرقه توربو أو دي تي في العمل من شخص لآخر ، ولكنه يستغرق عادةً ما بين نصف ساعة إلى ساعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ضع القرص القابل للذوبان في الفم ، على اللسان ، حيث سيذوب في ثوانٍ ، ثم ابتلعه باللعاب أو الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتناول الأقراص سريعة الذوبان بالفم على معدة فارغة حيث قد تجد أن الأمر يستغرق وقتًا أطول لبدء العمل إذا تناولتها مع وجبة ثقيلة.</p><p dir="RTL">إذا كنت بحاجة إلى قرص آخر 50 ملجم يذوب بالفم للحصول على جرعة 100 ملجم ، يجب عليك الانتظار حتى يذوب القرص الأول تمامًا وتكون قد ابتلعته قبل تناول القرص الثاني.</p><p dir="RTL">إذا شعرت أن تأثير توربو قوي جدًا أو ضعيف جدًا ، فتحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يساعدك توربو ف أو دي تي ي الحصول على الانتصاب فقط إذا تم تحفيزك جنسياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم يساعدك توربو أو دي تي في الحصول على الانتصاب ، أو إذا لم يستمر انتصابك لفترة كافية لإتمام الجماع الجنسي ، يجب عليك إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت توربو</strong> <strong>أو دي تي أكثر مما يجب</strong><strong>:</strong></p><p dir="RTL">قد تواجه زيادة في الآثار الجانبية وشدتها. الجرعات التي تزيد عن 100 ملجم لا تزيد من الفعالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب ألا تتناول أقراصًا أكثر مما أخبرك طبيبك</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن تسبب أقراص توربو سريعة الذوبان في الفم آثارًا جانبية على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">عادة ما تكون الآثار الجانبية المبلغ عنها عند استخدام توربو أو دي تي خفيفة إلى معتدلة وقصيرة المدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا واجهت أيًا من الآثار الجانبية الخطيرة التالية ، فتوقف عن تناول</strong><strong> </strong><strong>توربو</strong><strong> </strong><strong>أو دي تي </strong><strong>واطلب المساعدة الطبية على الفور</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي - يحدث هذا بشكل <strong>غير شائع</strong> (قد يؤثر على ما يصل إلى 1 من كل 100 شخص) وتشمل الأعراض الأزيز المفاجئ وصعوبة التنفس أو الدوخة وتورم الجفون والوجه والشفتين أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في الصدر (تحدث بشكل <strong>غير شائع</strong>)</p><p dir="RTL">إذا حدث هذا أثناء الجماع أو بعده:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اجلس في وضع شبه جلوس وحاول الاسترخاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تستخدم النترات</strong> لعلاج ألم صدرك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب طويل الأمد وأحيانًا مؤلم - <strong>نادرًا</strong> ما يحدث (قد يصيب 1 من كل 1000 شخص).</p><p dir="RTL">إذا كان لديك انتصاب يستمر لأكثر من 4 ساعات ، يجب عليك الاتصال بالطبيب فورا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مفاجئ في الرؤية أو فقدانها - <strong>نادراً</strong> ما تحدث.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل جلدية شديدة - <strong>نادراً</strong> ما تحدث.</p><p dir="RTL">قد تشمل الأعراض تقشرًا شديدًا وانتفاخًا في الجلد وتقرحات في الفم والأعضاء التناسلية وحول العينين وحمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات أو الصرع - <strong>نادرًا</strong> ما تحدث.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية أخرى</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدا</strong> (قد تظهر لدى أكثر من 1 من كل 10 أشخاص): صداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص): غثيان ، احمرار في الوجه ، تدفق ساخن (تشمل الأعراض شعور مفاجئ بالحرارة في الجزء العلوي من الجسم) ، عسر الهضم ، مسحة لونية في الرؤية ، عدم وضوح الرؤية ، اضطراب في الرؤية ، انسداد الأنف والدوخة .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد يؤثر على حتى 1 من كل 100 شخص): قيء ، طفح جلدي ، احمرار في العينين ، ألم في العين ، رؤية ومضات من الضوء ، سطوع بصري ، حساسية للضوء ، تدمع ، دقات قلب ، تسارع ضربات القلب ، ارتفاع ضغط الدم. انخفاض ضغط الدم ، آلام في العضلات ، نعاس ، انخفاض الحساسية للمس ، دوار ، طنين في الأذنين ، جفاف الفم ، انسداد الجيوب الأنفية ، التهاب بطانة الأنف (تشمل الأعراض سيلان الأنف ، العطس وانسداد الأنف) ، ألم في الجزء العلوي من البطن ، مرض ارتجاع معدي مريئي (تشمل الأعراض حرقة المعدة) ، دم في البول ، ألم في الذراعين أو الساقين ، نزيف في الأنف والشعور بالحرارة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>نادرة</strong> (قد يؤثر على حتى 1 من كل 1000 شخص): إغماء ، سكتة دماغية ، نوبة قلبية ، عدم انتظام ضربات القلب ، انخفاض مؤقت في تدفق الدم إلى أجزاء من الدماغ ، الشعور بضيق في الحلق ، خدر في الفم ، نزيف في مؤخرة العينين. رؤية مزدوجة ، انخفاض حدة الرؤية ، إحساس غير طبيعي في العين ، تورم العين أو الجفن ، نقاط أو جزيئات صغيرة في مجال الرؤية ، رؤية هالات حول الأضواء ، اتساع&nbsp;حدقة العين ، تغير في اللون الأبيض لبياض العين (جزء في العين) ، نزيف في القضيب ، دم في السائل المنوي ، جفاف الأنف ، انتفاخ بطانة الأنف ، تهيج ونقص مفاجئ في السمع.</p><p>تم الإبلاغ عن حالات نادرة من تجربة ما بعد التسويق مثل الذبحة الصدرية غير المستقرة (حالة قلبية) والموت المفاجئ. تجدر الإشارة إلى أن معظم الرجال الذين عانوا من هذه الآثار الجانبية ، وليس كلهم ، كانوا يعانون من مشاكل في القلب قبل تناول هذا الدواء. لا يمكن تحديد ما إذا كانت هذه الأحداث مرتبطة مباشرة بـ توربو أو دي تي.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أصبح أي من الآثار الجانبية خطير أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي و نظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول أقراص توربو أو دي تي بعد تاريخ انتهاء الصلاحية المذكور على الشريط أو العبوة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي سيلدينافيل. يحتوي كل قرص على سيلدينافيل سترات (دستور الأدوية الأوروبي) ما يعادل سيلدينافيل 50 ملجم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: مانيتول ، ميكروكريستالين سليلوز ، كروسبوفيدون ، كروسكارميلوز الصوديوم ، سكرالوز ، بوفيدون K-30 ، نكهة الليمون ، نكهة النعناع (C-7531) ، نكهة النعناع P96511-71 ، ستيرات المغنيسيوم, ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص سريعة الذوبان في الفم</p><p dir="RTL">أقراص لونها أبيض إلى أبيض داكن ، ماسية الشكل ، منقوش عليها &quot;CT42&quot; من جانب و منبسطة على الجانب الآخر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>حجم العبوة</strong><strong>:</strong></p><p dir="RTL">كل شريط من الألومنيوم يحتوي على 4 أقراص.</p><p dir="RTL">متوفر في عبوة تحتوي على 4 أقراص &nbsp;و عبوة تحتوي على 8 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة ( الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ (10/2020)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TURBO 50 mg orodispersible tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains sildenafil citrate, equivalent to 50 mg of sildenafil.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Orodispersible tablet.
White to off white coloured,diamond shaped tablets,debossed with “CT42” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TURBO is indicated in adult men with erectile dysfunction, i.e. with the inability to reach or to maintain an erection suitable for satisfactory sexual activity.</p><p>Sexual stimulation is required for TURBO to be effective.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p>&nbsp;</p><p><u>Use in adults</u></p><p>Turbo should be taken as needed about an hour before sexual activity. The recommended dose is 50 mg to be taken on an empty stomach, since concomitant food intake slows down absorption and delays the effect of the orodispersible tablet (see section 5.2).</p><p>Based on efficacy and tolerability, the dose can be increased to 100 mg. The maximum dose recommended is 100 mg. For patients who need a dose increase to 100 mg, they must two 50 mg orodispersible tablets should be administered sequentially. The product does not have to be administered more than once a day. If a 25 mg dose is required, use should be recommended of the 25 mg film-coated tablets.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>Elderly patients</p><p>Dosage adjustments are not required in elderly patients (&ge; 65 years).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The dosage recommendations described in the section &ldquo;Use in adults&rdquo; also apply to patients with mild to moderate renal impairment (creatinine clearance = 30-80 mL / min).</p><p>&nbsp;</p><p>Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance &lt;30 mL / min), a 25 mg dose should be considered. According to efficacy and tolerability, the dose can be gradually increased to 50 mg and up to 100 mg, as needed.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Since sildenafil clearance is reduced in patients with hepatic impairment (e.g. cirrhosis), a 25 mg dose must be considered. Based on efficacy and tolerability, the dose can be gradually increased to 50 mg and up to 100 mg as needed.</p><p>&nbsp;</p><p><u>Pediatric population:</u></p><p>TURBO is not indicated for people under the age of 18.</p><p>&nbsp;</p><p><u>Use in patients taking other medicines:</u></p><p>With the exception of ritonavir, for which co-administration with sildenafil is not recommended (see section 4.4) an initial dose of 25 mg should be considered in patients receiving a concomitant treatment with CYP3A4 inhibitors (see section 4.5).</p><p>Before starting sildenafil treatment, to minimize the development of postural hypotension in patients being treated with alpha-blockers, patients should be stabilized with a treatment based on alpha-blockers. In addition, the initiation of treatment must be considered with sildenafil at a dose of 25 mg (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.</p><p>The orodispersible tablet should be placed in the mouth, on the tongue, and allowed to disintegrate before swallow with or without water. The tablet should be taken immediately after removal from the blister. For patients who need a second 50 mg orodispersible tablet to get to a dose of 100 mg, the second tablet should be taken after the first one is completely disintegrated in the mouth.</p><p>When the orodispersible tablets are taken with a high-fat meal and not fasting, there is a significant delay in absorption (see section 5.2). It is recommended to take the orodispersible tablets on an empty stomach.</p><p>&nbsp;</p><p>Orodispersible tablets can be taken with or without water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In accordance with the established effects on the nitric oxide / cyclic guanosine monophosphate metabolic pathway
(cGMP) (see section 5.1), sildenafil has been shown to potentiate the hypotensive effects of nitrates and therefore co-administration with nitric oxide donors (such as amyl nitrite) or with nitrates in any form is contraindicated.
Co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulants, such as riociguat, is contraindicated because it could lead to symptomatic hypotension (see paragraph 4.5).

Products indicated for the treatment of erectile dysfunction, including sildenafil, should not be used in subjects for whom sexual activity is not recommended (e.g. patients with severe cardiovascular disorders diseases, such as unstable angina or severe heart failure).

TURBO is contraindicated in patients who have lost sight in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this event is related or not to previous use of a type 5 phosphodiesterase inhibitor (PDE5) (see section 4.4).

The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated until further information is available: severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before considering drug treatment, a medical history must be carried out and an objective examination in order to diagnose erectile dysfunction and determine the causes that may underlie the pathology.</p><p>&nbsp;</p><p><u>Cardiovascular risk factors</u></p><p>Since there is a percentage of cardiac risk associated with sexual activity, before starting any treatment for erectile dysfunction, doctors must examine the cardiovascular condition of patients. Sildenafil possesses vasodilatory properties which result in mild reductions and transient blood pressure (see section 5.1). Before prescribing sildenafil ,Physicians must carefully consider whether these vasodilatory effects may have any negative consequences in patients with certain underlying conditions, especially in combination with sexual activity. Patients most sensitive to vasodilatory effects include patients with obstruction of systolic output (e.g. aortic stenosis, obstructive hypertrophic cardiomyopathy) or those suffering from multiple system atrophy, a rare syndrome that manifests itself in the form of severe impaired autonomic control of blood pressure.</p><p>&nbsp;</p><p>TURBO enhances the hypotensive effect of nitrates (see section 4.3).</p><p>During the marketing phase of the product, in temporal association with the use of TURBO, Serious cardiovascular events including myocardial infarction, unstable angina, death</p><p>sudden cardiac, ventricular arrhythmias, cerebrovascular haemorrhage, transient ischemic attack,</p><p>hypertension and hypotension have been reported. Most, but not all, of these patients had pre-existing cardiovascular risk factors. Many events have been reported to have occurred during or immediately after sexual intercourse and some immediately after taking TURBO in the absence of sexual activity.</p><p>It is not possible to determine whether these events are directly related to these or other factors.</p><p>&nbsp;</p><p><u>Priapism</u></p><p>Products indicated for the treatment of erectile dysfunction, including sildenafil, must be used with caution in patients with anatomical deformations of the penis (e.g. angulation, fibrosis cavernosa or Peyronie&#39;s disease) or in patients with diseases that may predispose to priapism (such as sickle cell anemia, multiple myeloma or leukemia).</p><p>In post-marketing experience with sildenafil, prolonged erections and priapism have been reported.</p><p>If an erection persists for more than 4 hours, the patient should immediately seek medical attention. If priapism is not treated immediately penile tissue damage and permanent loss of potency could result.</p><p>&nbsp;</p><p><u>Concomitant use with other PDE5 inhibitors or with other treatments for erectile dysfunction</u></p><p>The safety and efficacy of combining sildenafil with other PDE5 inhibitors, with others treatments for pulmonary arterial hypertension (IAP) containing sildenafil (REVATIO), or with others treatments for erectile dysfunction have not been studied. Therefore, the use of these associations is not recommended.</p><p>&nbsp;</p><p><u>Effects on sight</u></p><p>Cases of visual disturbances have been reported spontaneously in association with the use of sildenafil and</p><p>of other PDE5 inhibitors (see section 4.8). Cases of non-arteritic anterior ischemic optic neuropathy, a rare disease, were reported spontaneously and in an observational study in association with the use of sildenafil and other PDE5 inhibitors (see section 4.8). The patients must be warned that in case of any sudden vision problem, they must stop</p><p>taking TURBO and immediately consult a doctor (see section 4.3).</p><p>&nbsp;</p><p><u>Concomitant use with ritonavir</u></p><p>Concomitant administration of sildenafil and ritonavir is not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Concomitant use with alpha-blockers</u></p><p>Caution is advised when sildenafil is administered to patients being treated with alpha-blockers as concomitant administration may cause symptomatic hypotension in some sensitive individuals (see section 4.5). This is most likely to occur within 4 hours subsequent to taking sildenafil. Before starting sildenafil treatment, to reduce to</p><p>minimal development of postural hypotension, patients should be stabilized from a point of view</p><p>hemodynamic with a treatment based on alpha-blockers. The beginning must be treatment with sildenafil at a dose of 25 mg (see section 4.2). Also, doctors must advise patients what to do in the presence of symptoms of postural hypotension.</p><p>&nbsp;</p><p><u>Effect on bleeding</u></p><p>Studies with human platelets indicate that sildenafil potentiates the antiplatelet effect of sodium nitroprusside in vitro. No information is available regarding the safety of the administration of sildenafil in patients with bleeding disorders or with active peptic ulcer.</p><p>Therefore, sildenafil should be administered to these patients only after careful evaluation of the risk-benefit ratio.</p><p>&nbsp;</p><p><u>Women</u></p><p>TURBO is not indicated for use in women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on sildenafil</u></p><p><em>In vitro studies</em></p><p>Sildenafil is mainly metabolised by isoenzymes 3A4 (major route) and 2C9 (secondary route) of cytochrome P450 (CYP). Therefore, inhibitors of these isoenzymes can reduce the clearance of sildenafil and inducers of these isoenzymes may increase sildenafil clearance.</p><p><em>In vivo studies</em></p><p>Population pharmacokinetic analysis in clinical studies indicates a reduction in clearance of sildenafil when given together with CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, cimetidine). Although there was no increased incidence in these patients adverse events, when sildenafil is co-administered with CYP3A4 inhibitors it must</p><p>consider a starting dose of 25 mg.</p><p>&nbsp;</p><p>When ritonavir, an HIV protease inhibitor and highly specific cytochrome inhibitor P450, was administered together with sildenafil (100 mg single dose), at steady state (500 mg twice daily) there was a 300% (4-fold) increase in sildenafil Cmax &nbsp;and a 1,000% (11-fold) increase in plasma AUC of sildenafil. At 24 hours later, sildenafil plasma levels were still approximately 200 ng / mL, compared with approximately 5 ng / mL detected when sildenafil was administered alone. This figure is in agreement with the effects that ritonavir exerts on a wide range of cytochrome P450 substrates. Sildenafil has not altered ritonavir pharmacokinetics. Based on these pharmacokinetic results, co-administration of sildenafil and ritonavir is not recommended (see section 4.4., and in any case the maximum dose of sildenafil should not exceed 25 mg within 48 hours.</p><p>&nbsp;</p><p>When saquinavir, an HIV protease inhibitor and CYP3A4 inhibitor, was co-administered with sildenafil (100 mg single dose), at steady state (1200 mg three times per day) there was a 140% increase in sildenafil Cmax and a 210% increase in the AUC of sildenafil. Sildenafil did not alter the pharmacokinetics of saquinavir (see section</p><p>4.2). Stronger CYP3A4 inhibitors, such as ketoconazole and itraconazole, are expected to have greater effects.</p><p>&nbsp;</p><p>When a single 100 mg dose of sildenafil was administered together with erythromycin, a moderate inhibitor of CYP3A4, at steady state (500 mg twice daily for 5 days) there was a 182% increase detected in sildenafil systemic exposure (AUC). In healthy volunteers no effect of azithromycin (500 mg / day for 3 days) on AUC, Cmax,</p><p>tmax, elimination constant or half-life of sildenafil or its major circulating metabolite. The concomitant administration of cimetidine (800 mg), cytochrome P450 inhibitor and a nonspecific CYP3A4, and sildenafil (50 mg) in healthy volunteers, caused a 56% increase in plasma concentrations of sildenafil.</p><p>&nbsp;</p><p>Grapefruit juice is a weak inhibitor of CYP3A4 of intestinal wall metabolism and therefore it may lead to modest increases in sildenafil plasma levels.</p><p>Administration of single doses of antacid (magnesium hydroxide / aluminum hydroxide) has not modified the bioavailability of sildenafil.</p><p>Although no specific interaction studies have been conducted with all medicines, the analysis Population pharmacokinetics showed no effect on the pharmacokinetics of sildenafil following concomitant treatment with CYP2C9 inhibitors (e.g. tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (e.g. selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide diuretics and the like, loop diuretics and potassium, angiotensin converting enzyme inhibitors, calcium channel blockers, antagonists beta-adrenergic receptors or inducers of CYP450 metabolism (e.g. rifampicin and barbiturates). In a study conducted on healthy male volunteers, the co-administration of the antagonist endothelin bosentan (an inducer of CYP3A4 [moderate], CYP2C9 and possibly CYP2C19) at steady state (125 mg twice daily) and sildenafil at steady state (80 mg three times daily</p><p>day) produced a decrease of 62.6% and 55.4% in the AUC and Cmax of sildenafil respectively. Therefore, concomitant administration of strong CYP3A4 inducers, such as rifampicin, may cause larger decreases in sildenafil plasma concentrations.</p><p>&nbsp;</p><p>Nicorandil is a hybrid that works as a nitrate and as a drug that activates potassium channels. In nitrate quality can lead to serious interactions when given together with sildenafil.</p><p>&nbsp;</p><p>Effects of sildenafil on other medicinal products</p><p><em>In vitro studies</em></p><p>Sildenafil is a weak inhibitor of cytochrome P450 isoenzymes: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50&gt; 150 &mu;M). Since peak plasma concentrations of approximately 1 &mu;M, TURBO is unlikely to alter the clearance of substrates of these isoenzymes.</p><p>There are no data on interactions between sildenafil and non-specific phosphodiesterase inhibitors, such as</p><p>theophylline or dipyridamole.</p><p>&nbsp;</p><p><em>In vivo studies</em></p><p>Consistent with the established effects on the nitric oxide / cGMP pathway (see section 5.1), Sildenafil has been observed to potentiate the hypotensive effects of nitrates and therefore co-administration with nitric oxide donors or with nitrates in any form is contraindicated</p><p>(see section 4.3).</p><p>&nbsp;</p><p>Riociguat: Preclinical studies have shown an additive systemic blood pressure reducing effect when PDE5 inhibitors have been combined with riociguat. Clinical studies have shown that riociguat increases the hypotensive effect of PDE5 inhibitors. There was no evidence of a clinical effect favorable association in the population studied. The concomitant use of riociguat with PDE5 inhibitors, including sildenafil, is contraindicated (see section 4.3).</p><p>Concomitant administration of sildenafil in patients on alpha-blocker therapy may cause symptomatic hypotension in some sensitive individuals. This is most likely to occur by 4 hours after taking sildenafil (see sections 4.2 and 4.4). In three direct interaction studies the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg or 100 mg) were co-administered in patients with benign prostatic hypertrophy (BPH) stabilized with doxazosin-based therapy. Mean reductions were observed in these population studies</p><p>additional supine pressure of 7/7 mmHg, 9/5 mmHg and 8/4 mmHg respectively and mean additional reductions in standing blood pressure of 6/6 mmHg respectively, 11/4 mmHg and 4/5 mmHg. When sildenafil and doxazosin were administered together in patients stabilized with doxazosin therapy have rarely been reported</p><p>reported symptomatic postural hypotension. These cases included dizziness and confusion of the mind, but not syncope.</p><p>No significant interactions were observed when sildenafil (50 mg) was administered together with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9.</p><p>Sildenafil (50 mg) did not enhance the increase in bleeding time caused by the acetylsalicylic acid (150 mg).</p><p>Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with levels</p><p>maximum blood alcohol levels corresponding on average to 80 mg / dl.</p><p>The analysis of data relating to the following classes of antihypertensive drugs did not reveal any difference in tolerability profile between patients who took sildenafil and those treated with placebo: diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensives (vasodilator and centrally acting), neuroadrenergic blockers, calcium channel blockers and alpha adrenoceptors. During a specific interaction study, in which sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, the additional reduction in blood pressure</p><p>supine systolic was 8 mmHg. The corresponding additional reduction on the Supine diastolic blood pressure was 7 mmHg.</p><p>These additional blood pressure reductions were comparable to those seen when sildenafil was administered as monotherapy to healthy volunteers (see section 5.1).</p><p>Sildenafil (100 mg) did not alter the steady-state pharmacokinetics of the inhibitors HIV protease, saquinavir and ritonavir, which are both substrates of CYP3A4.</p><p>In healthy male volunteers, steady state sildenafil (80 mg three times daily) caused an increase by 49.8% of the AUC of bosentan and a 42% increase in the Cmax of bosentan (125 mg twice daily day).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of TURBO in women is not indicated.</p><p>There are no adequate and well-controlled studies on the use of the medicine during pregnancy or during breastfeeding.</p><p>In reproduction studies in rats and rabbits following oral administration of sildenafil no relevant adverse events were found.</p><p>No effect on sperm motility or morphology was observed following the administration of single oral doses of 100 mg sildenafil to healthy volunteers (see section 5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TURBO may have a slight influence on the ability to drive and use machines.</p><p>Since dizziness and visual disturbances have been reported in clinical trials with sildenafil,</p><p>patients should be aware of how react to TURBO before driving and operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile of TURBO is based on 9570 patients treated with the dosing regimen recommended in 74 double-blind placebo-controlled clinical trials. The most adverse reactions commonly reported in patients treated with sildenafil in clinical trials are headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, flushing, visual discomfort, cyanopsia and blurred vision.</p><p>Adverse reactions from post-marketing surveillance have been collected from a period</p><p>estimated&gt; 10 years. As not all adverse reactions are reported to the holder of the marketing authorization and included in the pharmacovigilance database, the frequencies of these reactions cannot be reliably established.</p><p>&nbsp;</p><p><u>Tabular list of adverse reactions</u></p><p>The table below lists all clinically important adverse reactions, which occurred and verified in clinical trials with an incidence higher than that of placebo and are divided by system organ class and frequency (very common (&ge;1 / 10), common (&ge;1 / 100 to &lt;1/10), uncommon (&ge;1 / 1,000 to &lt;1/100), rare (&ge;1 / 10,000 to &lt;1 / 1,000).</p><p>Within each frequency class, the undesirable effects are reported in order of severity decreasing.</p><p>&nbsp;</p><p><strong>Table 1: Clinically important adverse reactions reported with an incidence greater than that of placebo in controlled clinical trials and clinically adverse reactions important ones reported during post-marketing surveillance.</strong></p><p><strong><u>&nbsp;</u></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very</strong></p><p><strong>common</strong></p><p><strong>(</strong>&sup3;<strong> 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(</strong>&sup3;<strong> 1/100 and</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(</strong>&sup3;<strong> 1/1000 and</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(</strong>&sup3;<strong> 1/10,000</strong></p><p><strong>and &lt;1/1000)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and</p><p>infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence, hypoesthesia</p></td><td style="vertical-align:top"><p>Cerebrovascular accidents, transient ischemic attack, convulsions *, recurrent convulsions *, syncope</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Altered perception of colors **, visual disturbances, blurred vision</p></td><td style="vertical-align:top"><p>Lacrimation disorders ***, eye pain, photophobia, photopsia, ocular hyperaemia, increased perception of light, conjunctivitis</p></td><td style="vertical-align:top"><p>Non-arteritic anterior ischemic optic neuropathy (NAION) *, retinal vascular occlusion *, retinal haemorrhage, arteriosclerotic retinopathy, retinal pathology, glaucoma, visual field defects, diplopia, reduced visual acuity, myopia, asthenopia, fly flies, pathology of the iris, mydriasis, halo vision, eye edema,</p><p>eye swelling, eye disorders, conjunctival hyperaemia,</p><p>eye irritation, abnormal eye sensitivity, eyelid edema, discoloration of the sclera</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo, tinnitus</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia;</p><p>Palpitations</p></td><td style="vertical-align:top"><p>Sudden cardiac death *, heart attack</p><p>myocardial, ventricular arrhythmia *,</p><p>atrial fibrillation, unstable angina</p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hot flush;</p><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p><p>thoracic and</p><p>mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nasal</p><p>congestion</p></td><td style="vertical-align:top"><p>Epistaxis;</p><p>Sinus congestion</p></td><td style="vertical-align:top"><p>Throat</p><p>tightness;</p><p>Nasal dryness;</p><p>Nasal oedema</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea;</p><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Gastroesophageal reflux disease, vomiting, upper abdominal pain, dry mouth</p></td><td style="vertical-align:top"><p>Hypoaesthesia</p><p>oral</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Stevens-Johnson Syndrome</p><p>(SJS) *, necrotic epidermolysis</p><p>toxic (TEN) *</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal</p><p>and connective</p><p>tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia;</p><p>Pain in extremity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive</p><p>system and</p><p>breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Penile haemorrhage, priapism *, haematospermia, prolonged erections</p></td></tr><tr><td style="vertical-align:top"><p>General</p><p>disorders and</p><p>administration</p><p>site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Chest pain, fatigue, feeling of heat</p></td><td style="vertical-align:top"><p>Irritability</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Heart rate</p><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* Reported only during post-marketing surveillance.</p><p>** Distortions of color vision: Chloropsia, achromatopsia, Cyanopsia, Erythropsia and Xantopsia</p><p>*** Lacrimation Disorders: Dry eye, lacrimation disorders and increased tearing<strong><u> </u></strong></p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p><strong>&nbsp;</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single dose studies in volunteers up to 800 mg, adverse reactions were similar to those seen with lower doses, but the incidence rate and severity of events were increased.</p><p>The administration of 200 mg doses did not result in an increase in efficacy, but the incidence of adverse reactions (headache, hot flashes, dizziness, dyspepsia, nasal congestion, visual disturbances) increased.</p><p>In the event of an overdose, necessary standard supportive measures should be employed.</p><p>Hemodialysis does not accelerate renal clearance because sildenafil is highly bound to plasma proteins and is not eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: urologicals; drugs used for erectile dysfunction. ATC code G04B E03.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Sildenafil represents an oral therapy for erectile dysfunction. Under normal conditions, i.e. in the presence of sexual stimulation, sildenafil restores impaired erectile function by increasing blood flow to the penis.</p><p>&nbsp;</p><p>The physiological mechanism responsible for penile erection involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. Nitric oxide in turn activates the enzyme guanyl cyclase which causes an increase in the levels of cyclic guanosine monophosphate (cGMP), producing relaxation of smooth muscle in the corpus cavernosum and thus allowing the blood supply.</p><p>&nbsp;</p><p>Sildenafil is a potent selective inhibitor of cGMP-specific type 5 phosphodiesterase (PDE5) in the corpus cavernosum, where PDE5 is responsible for the breakdown of cGMP. Sildenafil acts peripherally on erections. Sildenafil does not have a direct relaxing effect on the corpus cavernosum isolated from humans, but it effectively increases the relaxing effect of nitric oxide (NO) on this tissue. When the NO / cGMP pathway is activated, as occurs with sexual stimulation, the inhibition of PDE5 by sildenafil causes an increase in cGMP levels in the corpus cavernosum. Therefore, sexual stimulation is required for sildenafil to produce its expected beneficial pharmacological effects.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>In vitro studies have shown that sildenafil has a selectivity for PDE5, which is involved in the erection process. Its effect is higher for PDE5 than for other phosphodiesterases. It has a 10-fold selectivity for PDE6, which is involved in phototransduction of the retina. At maximum recommended doses, it has 80-fold selectivity for PDE1 and over 700-fold for PDE2, 3, 4, 7, 8, 9, 10 and 11. Specifically, sildenafil&#39;s selectivity for PDE5 is 4,000-fold higher to that for PDE3, the specific cAMP phosphodiesterase isoenzyme involved in the control of cardiac contractility.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Two clinical studies were conducted to specifically evaluate the time interval after taking the drug within which sildenafil can produce an erection in response to the sexual stimulus. In a study conducted with penile plethysmography (RigiScan) in patients on an empty stomach, the mean time to onset in sildenafil-treated subjects who had erections with 60% stiffness (sufficient for intercourse) was 25 minutes ( range 12-37 minutes). In another study with RigiScan, still 4-5 hours after administration sildenafil produced an erection in response to sexual stimulation.</p><p>&nbsp;</p><p>Sildenafil causes mild and transient decreases in blood pressure which, in most cases, do not translate into clinical effects. The mean of the maximum reductions in supine systolic blood pressure following oral administration of 100 mg of sildenafil was 8.4 mmHg. The corresponding change in supine diastolic blood pressure was 5.5 mmHg. These blood pressure reductions are part of the vasodilatory effects of sildenafil, possibly due to the increased levels of cGMP in smooth vascular muscle. Administration of single oral doses of sildenafil up to 100 mg to healthy volunteers produced no clinically relevant effects on ECG.</p><p>&nbsp;</p><p>In a study on the haemodynamic effects of a single oral dose of 100 mg sildenafil conducted on 14 patients with severe coronary artery disease (CAD) (stenosis of at least one coronary artery&gt; 70%), the mean resting systolic and diastolic blood pressure decreased by 7% and 6% respectively from baseline. Mean systolic pulmonary pressure decreased by 9%. Sildenafil did not alter cardiac output and did not impair blood circulation through stenotic coronary arteries.</p><p>&nbsp;</p><p>A double-blind, placebo-controlled study evaluated 144 patients with erectile dysfunction and chronic stable angina undergoing exercise testing who regularly took antianginal medicines (with the exception of nitrates). The results showed no clinically relevant differences between sildenafil and placebo with regard to the time taken to limit angina.</p><p>&nbsp;</p><p>In some subjects, with the aid of the Farnsworth-Munsell 100 HUE test, slight and transient changes in color perception (blue / green) were detected one hour after the administration of a dose of 100 mg, without evident effects 2 hours after administration. It is assumed that the mechanism underlying this alteration in color perception is related to the inhibition of PDE6, which is involved in the cascade phototransduction in the retina. Sildenafil does not affect visual acuity or color sense. In a placebo-controlled study in a small number of patients (n = 9) with documented early age-related macular degeneration, the use of sildenafil (single 100 mg dose) did not show clinically significant changes in the vision tests (visual acuity, Amsler reticle, ability to perceive colors with simulation of traffic lights, Humprey perimetry and photostress).</p><p>&nbsp;</p><p>No effect on sperm motility or morphology was observed following administration of single oral doses of 100 mg sildenafil to healthy volunteers (see section 4.6).</p><p>&nbsp;</p><p><em>Learn more about clinical trials</em></p><p>In clinical trials, sildenafil has been administered to over 8000 patients aged 19 to 87 years. The following patient groups were included: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischemic heart disease (5.8%), hyperlipidemia (19.8 %), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%). The following patient groups were not significantly</p><p>represented or excluded from clinical trials: patients undergoing pelvic surgery, patients undergoing radiotherapy, patients with severe renal or hepatic impairment and patients with specific cardiovascular conditions (see section 4.3).</p><p>&nbsp;</p><p>In the fixed dose clinical trials, the percentage of patients who reported improvement was 62% (25 mg), 74% (50 mg) and 82% (100 mg), compared with 25% reported with placebo. In controlled clinical trials, the discontinuation rate due to sildenafil was low and similar to that reported with placebo.</p><p>&nbsp;</p><p>In all clinical studies the percentage of patients who reported improvement during sildenafil treatment was as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly ( 67%), diabetes mellitus (59%), ischemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75% ). The safety and efficacy of sildenafil was maintained in long-term studies.</p><p>&nbsp;</p><p><u>Pediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies for the treatment of erectile dysfunction with TURBO in all subsets of the pediatric population. See section 4.2 for information on pediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Sildenafil is rapidly absorbed. Maximum plasma concentrations are reached within 30-120 minutes (mean 60 minutes) of oral administration in the fasted state. The mean absolute bioavailability after oral administration is 41% (range 25-63%). After oral administration of sildenafil, when the drug is used at the recommended dose range (25-100 mg), AUC and C increase in proportion to the dose.</p><p>When the film-coated tablets are taken with meals, the absorption rate of sildenafil is reduced with a mean delay in tmax of 60 minutes and a mean reduction in Cmax of 29%.</p><p>&nbsp;</p><p>In a clinical study conducted on 36 healthy males aged 45 or older, the 50 mg orodispersible tablets taken without water were shown to be bioequivalent to the 50 mg film-coated tablets. In the same study, the AUC was unchanged, but the mean Cmax was 14% lower when the 50 mg orodispersible tablets were administered with water compared to the 50 mg film-coated tablets.</p><p>&nbsp;</p><p>When the orodispersible tablets are taken with a high-fat meal, the absorption rate of sildenafil is reduced, with a median delay in T of approximately 3.4 hours and a reduction in mean C and AUC of respectively. approximately 59% and 12%, compared with the administration of orodispersible tablets in the fasted state (see section 4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The mean steady-state volume of distribution of sildenafil (Vd), i.e. distribution into tissues, is 105 L. Following the use of a single 100 mg oral dose, the mean maximum plasma concentration of sildenafil is approximately 440 ng / mL (CV 40%). Since sildenafil (and its major circulating metabolite N-desmethyl) is 96% bound to plasma proteins, this results in a mean maximum free sildenafil plasma concentration of 18 ng / mL (38 nM).</p><p>Protein binding is independent of total drug concentrations.</p><p>In healthy volunteers who received sildenafil (100 mg single dose), amounts of less than 0.0002% (mean 188 ng) of the administered dose were detected in the ejaculate obtained 90 minutes after administration.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Sildenafil is primarily metabolised by hepatic microsomal isoenzymes CYP3A4 (major route) and CYP2C9 (secondary route). The main metabolite is derived from the N-demethylation of sildenafil. This metabolite has a selectivity profile for phosphodiesterase similar to that of sildenafil and an in vitro potency for PDE5 equal to approximately 50% of that of the parent drug.</p><p>Plasma concentrations of this metabolite are approximately 40% of those observed for sildenafil. The N-desmethyl metabolite is further metabolized, with a terminal half-life of approximately 4 hours.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The total body clearance of sildenafil is 41 L / h and the terminal half-life is 3-5 hours. After oral or intravenous administration, sildenafil is eliminated in the form of metabolites, mainly in the faeces (approximately 80% of the oral dose administered) and to a lesser extent in the urine (approximately 13% of the oral dose administered).</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups :</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>In elderly healthy volunteers (&ge; 65 years) a reduction in sildenafil clearance was observed, with plasma concentrations of sildenafil and the active metabolite N-desmethyl approximately 90% above those found in younger healthy volunteers (18-45 years). Due to age-related differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentrations was approximately 40%.</p><p>&nbsp;</p><p><em>Renal Insufficiency </em></p><p>In volunteers with mild to moderate renal impairment (creatinine clearance = 30-80 mL / min), no alterations in the pharmacokinetics of sildenafil were observed following administration of a single 50 mg oral dose. The mean AUC and Cmax of the metabolite N-desmethyl increased by up to 126% and up to 73%, respectively, compared to comparable age volunteers who did not have renal impairment. However, due to the high inter-subject variability, these differences were not statistically significant. In volunteers with severe renal impairment (creatinine clearance &lt;30 mL / min) a reduction in sildenafil clearance was observed, resulting in mean increases in AUC (100%) and Cmax (88%) compared to comparable age volunteers who they did not have renal impairment. Furthermore, the AUC and Cmax of the N-desmethyl metabolite increased significantly, by 200% and 79%, respectively.</p><p>&nbsp;</p><p><em>Hepatic insufficiency</em></p><p>In volunteers with mild-to-moderate liver cirrhosis (Child-Pugh A and B), a reduction in sildenafil clearance was observed, resulting in an increase in AUC (84%) and Cmax (47%), compared to volunteers of comparable age which did not show hepatic impairment. The pharmacokinetics of sildenafil in patients with severe hepatic impairment have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special risks for humans based on conventional studies of pharmacological safety, repeated dose toxicity, genotoxicity, carcinogenic potential, reproductive and developmental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Microcrystalline cellulose</p><p>Crospovidone</p><p>Croscarmellose sodium</p><p>Sucralose</p><p>Povidone K-30</p><p>Lemon Flavour</p><p>Peppermint flavour (C-7531)</p><p>Peppermint flavour P96511-71</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg; C</p><p>Store in the original carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/Alu Blister pack 4&rsquo;s count and 4 tablets per box.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep all medicine out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>